Abstract:Purpose: Lung cancer is the most common malignancy with the highest morbidity and mortality worldwide. Low-dose computed tomography (LDCT) is one of the main tools for lung cancer screening and diagnosis. However, high false positive, high cost, over-diagnosis and radiation exposure are major drawbacks to screen pulmonary nodules by LDCT. Thus, a noninvasive diagnostic approach with high specificity and accuracy is badly needed to enhance LDCT. Liquid biopsy represent a valuable non-invasive approach when biopsy or resection is not the first choice. Till now, it is rare to see the studies on exosome-derived miRNAs as early diagnosis biomarkers to distinguish benign and malignant pulmonary nodules using small RNA sequencing. Here, we aimed to explore the diagnostic value of a panel of significantly differential expressed plasma exosomal miRNAs between benign and malignant pulmonary nodule samples in Chinese cohorts. Materials and Methods: This study was registered at Chinese Clinical Trial Registry (www.chictr.org.cn) with registration number ChiCTR1800019877. Forty-five patients including twenty-six lung adenocarcinoma and nineteen benign nodules with various pathological characteristics were enrolled as a training cohort. A test cohort consisted of sixty-two patients with twenty-four benign nodules patients similar to training cohort and thirty-eight lung adenocarcinoma. Exosomes were precipitated from the plasma, and small RNA sequencing was performed to identify the differential expressed miRNAs. A statistical model consisting of a panel of exosomal miRNAs was trained to discriminate benign nodules from cancerous ones. The model was validated in the independent test cohort, and re-confirmed in an external dataset from another Chinese cohort. Enriched Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were also performed. Results: Characteristic proteins and morphology of exosomes were characterised by western blotting, nanoparticle tracking analysis and scanning electron microscopy. Five differential expressed miRNAs (let-7b-3p, miR-101-3p, miR-125b-5p, miR-150-5p, and miR-3168) with median expression \u003e 50 were selected by LASSO-penalized regression as a linear model to classify samples into benign or maligant groups with 10-fold cross-validation to determine the model parameters. When the specificity set 94.7% and 91.7% for the training and test cohorts, respectively, the model had 57.7% and 57.9% sensitivity in both cohorts. The model was also confirmed in an external dataset with 87.5% specificity and 53.1% sensitivity. The expression of each biomarker in benign, adenocarcinoma in situ/microinvasive adenocarcinoma and invasive adenocarcinoma nodules were gradually altered. Four of the five biomarkers were gradually increased, whereas one miRNA was gradually decreased. GO and KEGG analysis demonstrated that biological process and pathways of the genes targeted by five biomarkers were associated with tumor development. Conclusions: This study using small RNA sequencing identified five plasma exosome-derived differentially expressed miRNAs as a diagnosis model to distinguish benign and malignant pulmonary nodules, which provides insights into the feasibility of exosomal miRNAs as a novel early diagnosis approach for lung adenocarcinoma. Citation Format: Di Zheng, Yang Yang, Chunyan Wu, Huizhen Wang, Jiyang Zhang, Shiyi Liu, Xiaoya Xu, Hao Chen, Dadong Zhang, Fugen Li, Jian Ni, Gening Jiang, Jianfang Xu. A panel of plasma exosomal miRNAs as diagnosis biomarker to distinguish benign and malignant nodules in non-small cell lung cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 756.

Circulating Plasma Exosomal Long Non-Coding RNAs LINC00265, LINC00467, UCA1, and SNHG1 As Biomarkers for Diagnosis and Treatment Monitoring of Acute Myeloid Leukemia.

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients.

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Construction of an Immune-Related Prognostic Signature and lncRNA‒miRNA–mRNA ceRNA Network in Acute Myeloid Leukaemia

Genome-wide characterization of lncRNAs in acute myeloid leukemia.

Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia

Identification Of Circulating Long Noncoding Rna Linc00152 As A Novel Biomarker For Diagnosis And Monitoring Of Non-Small-Cell Lung Cancer

Circulating lnc-LOC as a novel noninvasive biomarker in the treatment surveillance of acute promyelocytic leukaemia

LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia

Plasma-derived exosomal long noncoding RNAs of pancreatic cancer patients as novel blood-based biomarkers of disease

Plasma Extracellular Vesicle Long RNA in Diagnosis and Prediction in Small Cell Lung Cancer.

Plasma exosomes contain protein biomarkers valuable for the diagnosis of lung cancer

A panel of plasma exosomal miRNAs as diagnosis biomarker to distinguish benign and malignant nodules in non-small cell lung cancer

Integrated plasma and exosome long noncoding RNA profiling is promising for diagnosing non-small cell lung cancer

Abstract 867: Identifying plasma exosomal small non-coding RNAs as potential biomarkers for lung cancer early detection

Plasma long non-coding RNAs as biomarkers for bone marrow infiltration and stage in diffuse large B-cell lymphoma

Identification of Exosome Protein Panels As Predictive Biomarkers for Non-Small Cell Lung Cancer

Utilizing exosomes as sparking clinical biomarkers and therapeutic response in acute myeloid leukemia